BioIVT Xpressway Profile Safety Package

BioIVT has launched the Xpressway Profile Safety Package, a compendium of 46 expression profiles for genes known to play pivotal roles in drug safety assessments. These genes are included in the initial screening panel used by pharmaceutical companies to evaluate new chemical entities for potential off-target interactions and toxic effects. Once these entities have been screened against the 46 target genes, the Xpressway Profile Safety Package allows the resulting binding data to be compared with the corresponding human target expression profiles and interpreted further to assess potential safety risk, the company said. When NCEs bind to the targets, the tissue distribution of those targets can inform decision making about the compounds and chemical series. BioIVT said that it employed a rigorous, highly controlled qRT-PCR method to develop the Xpressway Profile Safety Package's gene expression data.